高盛坚定看好礼来,押注“生物制药史上最强产品周期”。 据追风交易台,高盛股票研究部门于10月31日发布研报,称礼来的口服减肥候选药物orforglipron代表着“整个生物制药覆盖范围内最重要的新产品周期之一”。管理层透露全球监管提交即将开始,预计明年在美国市场推出用于肥胖治疗。 礼来正以扎实的业绩兑现和前瞻性的创新布局,巩固其在全球生物医药产业的龙头地位。 GLP-1霸主地位持续扩张 据华尔街...
Source Link高盛坚定看好礼来,押注“生物制药史上最强产品周期”。 据追风交易台,高盛股票研究部门于10月31日发布研报,称礼来的口服减肥候选药物orforglipron代表着“整个生物制药覆盖范围内最重要的新产品周期之一”。管理层透露全球监管提交即将开始,预计明年在美国市场推出用于肥胖治疗。 礼来正以扎实的业绩兑现和前瞻性的创新布局,巩固其在全球生物医药产业的龙头地位。 GLP-1霸主地位持续扩张 据华尔街...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.